First clinical trial of vosoritide for children with hypochondroplasia shows increased growth
Vosoritide's first global Phase II study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of short stature in children, according to researchers from Children's ...